NEJM: Prevention of adverse prognosis for peripheral arterial disease in patients with peripheral artery disease used in vascular reconstruction
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, researchers examined the effect of Delavaban on the prevention of major adverse limb and cardiovascular events in patients with peripheral artery disease in the lower extremitiespatients with peripheral artery disease who received vascular reconstruction in a double-blind trial were randomly given delavsaban (2.5 mg) or a placebo on an aspirin basisThe main therapeutic endpoints were acute limb ischemia, amputation due to vascular causes, myocardial infarction, ischemic stroke or cardiovascular deathThe main safety endpoint is hemorrhage, and secondary safety outcomes include TIMI and ISTH standard bleeding events6,564 patients participated in the study, including 3,286 in the Dewarsha class and 3,278 in the placebo groupThe main endpoint events occurred in 508 people in the Devalia group and 584 in the placebo group, with a three-year event rate of 17.3% and 19.9% respectively (HR-0.85)There were 62 TIMI haemorrhage events in the Devashaban group, 44 in the placebo group (2.65 vs 1.87%, HR 1.43), 140 STH haemorrhage events in the Devasha ban group, and 100 in the placebo group (5.94 vs 4.06%, HR?1.42)studies have concluded that for patients with peripheral artery disease who receive vascular reconstruction, adding delavata sabans on the basis of aspirin therapy can effectively reduce the risk of adverse limb and cardiovascular prognosis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
